Exploring the value of theragnostic radionuclide therapies
within advanced oncology
Following the hugely successful meeting in 2019, the 2nd Targeted Radiopharmaceuticals (TRP) Summit returns this year in exclusive virtual format.
You can expect a wider array of insights from recent case studies to help you accelerate the development of the next-generation of radioligand therapies from clinical approval to commercialisation.
As the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radio ligand therapies, we strive to tackle topics that are on every drug developer’s mind:
- How do we identify and validate new targets?
- Can we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology method?
- How do we improve current clinical design methodologies and patient selection strategies?
- Where can improvements be made to the current supply and fulfilment models?
To see the wide variety of talks, panels and speakers tackling these issues, download the full event guide here